Skip to main content
. 2023 Jul 6;11(19):4601–4611. doi: 10.12998/wjcc.v11.i19.4601

Table 1.

Comparison of baseline data


UTI group (n = 91)
Placebo group (n = 90)
P value
Age (year, mean ± SD) 52.7 ± 3.8 53.5 ± 4.1 0.175
Gender, n (%) 0.705
    Male 67 (73.63) 64 (71.11)
    Female 24 (26.37) 26 (28.88)
BMI (kg/cm2, mean ± SD) 22.6 ± 2.1 23.1 ± 2.5 0.147
Cause of disease, n (%) 0.582
    Biliary 61 (67.03) 57 (63.33)
    Hyperlipidemic 18 (19.78) 19 (21.11)
    Alcoholic 12 (13.09) 14 (15.56)
Smoking history, n (%) 0.483
    Yes 53 (58.24) 57 (63.33)
    No 38 (41.76) 33 (36.67)
Drinking history, n (%) 0.371
    Yes 58 (58.24) 63 (70.00)
    No 33 (41.76) 27 (30.00)
Living environment, n (%) 0.604
    Town 59 (64.84) 55 (61.11)
    Countryside 32 (35.16) 35 (38.89)
Past medical history, n (%)
    Hypertension 31 (34.07) 29 (32.22) 0.792
    Hyperlipidemia 35 (38.46) 37 (41.11) 0.716
    Diabetes 28 (30.77) 29 (32.22) 0.833
    Cholelithiasis 17 (18.68) 16 (17.78) 0.875
Previous pancreatitis, n (%) 9 (9.89) 10 (11.11) 0.789
APACHE-II score on admission (mean ± SEM) 12.6 ± 0.8 12.2 ± 0.8 0.724
Ranson score on admission (mean ± SEM) 3.3 ± 0.3 3.2 ± 0.4 0.842
Necrotizing pancreatitis 23 (25.27) 20 (22.22) 0.727
Time from the onset to diagnosis (hours) 15.2 ± 6.5 14.6 ± 7.1 0.950
Endoscopic bile duct drainage 37 (40.66) 42 (46.67) 0.455

UTI: Ulinastatin: BMI: Body mass index; APACHE: Acute Physiology and Chronic Health Evaluation.